Section of Hepatology, Departments of Medicine, University of Manitoba, Winnipeg, MB, Canada; Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada.
J Viral Hepat. 2013 Dec;20(12):890-6. doi: 10.1111/jvh.12121. Epub 2013 May 29.
Clinical observations suggest that chronic hepatitis B virus (HBV) infections in the Canadian Inuit are less often associated with serious adverse outcomes than has been described in other HBV-infected patient populations. The aim of this study was to document the clinical and biochemical features, liver-related morbidity and all-cause mortality in Canadian Inuit with chronic HBV infections. Administrative databases were reviewed for individuals identified as hepatitis B surface antigen (HBsAg) positive during a 1983-85 seroepidemiological survey of viral hepatitis in Baffin Island, Canada. An equal number of age- and gender-matched HBsAg-negative individuals from the same communities served as controls. Baseline HBV viral loads, genotypes and specific mutations were compared in HBsAg-positive survivors and nonsurvivors. A subset of surviving HBsAg-positive carriers were reassessed 25-30 years following their initial diagnosis for evidence of advanced liver disease and changes to their serological/virological findings. One hundred and forty four HBsAg-positive individuals were identified. All were Canadian Inuit. The mean age at diagnosis was 38 ± 17 years and 69 (61%) were male. Median follow-up was 23 years (range: 2-28 years). Viral quantitation from stored sera could be performed in 70 infected individuals. The median viral load was 4.3 log 10 IU/ml (range: 2.3-8.8 log 10 IU/ml), and all were genotype B, subgenotype B6. Liver biochemistry, morbidity and all-cause mortality rates were similar in HBsAg-positive carriers and controls. Following multivariate analyses, only age at diagnosis predicted mortality in HBsAg carriers. In a subset of 30 HBsAg-positive survivors who underwent follow-up assessments, clinical, biochemical and radiological examinations of the liver were essentially normal. 23/30 (77%) remained HBsAg positive and 17/19 (90%) HBV-DNA positive. The genotype and prevalence of genomic mutations in this cohort remained largely unchanged, but quantifiable viral loads were significantly lower (P < 0.003). The results of this study suggest that chronic HBV infections in the Canadian Inuit are infrequently associated with serious adverse outcomes. Whether this finding reflects unique features of the host, presence or absence of external factors that influence the course of HBV and/or intrinsic properties of the HBV B6 subgenotype remains to be determined.
临床观察表明,与其他乙型肝炎病毒 (HBV) 感染患者群体相比,加拿大因纽特人慢性 HBV 感染较少出现严重不良后果。本研究旨在记录加拿大因纽特慢性 HBV 感染者的临床和生化特征、与肝脏相关的发病率和全因死亡率。对 1983-1985 年在加拿大巴芬岛进行的病毒性肝炎血清流行病学调查期间确定为乙型肝炎表面抗原 (HBsAg) 阳性的个体进行了行政数据库审查。来自同一社区的相同数量的 HBsAg 阴性个体作为对照。比较 HBsAg 阳性幸存者和非幸存者的基线 HBV 病毒载量、基因型和特定突变。对一组幸存的 HBsAg 阳性携带者进行了重新评估,以评估他们在最初诊断后 25-30 年是否有晚期肝病证据以及他们的血清学/病毒学发现是否有变化。确定了 144 名 HBsAg 阳性个体。均为加拿大因纽特人。诊断时的平均年龄为 38 ± 17 岁,69 名(61%)为男性。中位随访时间为 23 年(范围:2-28 年)。可对 70 名感染者的储存血清进行病毒定量。中位病毒载量为 4.3 log 10 IU/ml(范围:2.3-8.8 log 10 IU/ml),均为基因型 B,亚基因型 B6。HBsAg 阳性携带者和对照组的肝功能生化指标、发病率和全因死亡率相似。多变量分析后,仅诊断时的年龄预测了 HBsAg 携带者的死亡率。在接受随访评估的 30 名 HBsAg 阳性幸存者中,对肝脏进行了临床、生化和影像学检查,结果基本正常。30 名中有 23 名(77%)仍为 HBsAg 阳性,19 名中有 17 名(90%)HBV-DNA 阳性。该队列的基因型和基因组突变的流行率基本保持不变,但可定量的病毒载量明显较低(P < 0.003)。本研究结果表明,加拿大因纽特人的慢性 HBV 感染很少与严重不良后果相关。这一发现是否反映了宿主的独特特征、影响 HBV 病程的外部因素的存在或缺失,以及 HBV B6 亚基因型的内在特性,还有待确定。